Navigation Links


Recurrent at Biology News

Recurrent at Biology Products
Recurrent at Biology Technology
Recurrent at Medicine News

Estrogen Does Not Prevent Recurrent Strokes

Despite some past evidence that hormone replacement might lower stroke risk in older women, new research shows that estrogen therapy does not protect women from recurrent strokes and may instead carry some risks. The findings add to growing evidence that hormone replacement therapy does not have the cardiovascular benefits doctors once believed. // Many doctors have long thought hormo...

Radiation Therapy An Effective Solution For Recurrent Prostate Cancer

Specialists say about 30,000 men in the United States who undergo surgery to have their prostates removed will have their cancer return.// However a recent study shows that men who have their prostates removed may benefit from radiation therapy if their cancer returns . Researchers studied more than 500 men with prostate cancer. All the men in the study first had a radical prostatectomy...

Prevention Of Recurrent Leg Ulcers

Latest research shows that combination treatment proves to be the best option to substantially reduce the risk of recurrent leg ulcers.// Surgery to remove part of the affected vein in addition to compression treatment was investigated as a new treatment option for leg ulcers .Surgery did not present any additional benefit in terms of venous ulcer healing, but recurrence rates were sign...

Heparin does not protect from recurrent heart attacks

Professor Mahaffey and his team from Duke Clinical Research Institute have found that either form of heparin (both low molecular weight and unfractionated)gives emergency// protection to heart attack patients by breaking the clots in blood flow to the heart reducing the risk of heart attacks for 24 hours. Though both the forms of heparin gives emergency treatment they are not found to avoid the r...

Measuring Urinary Protein Helps In Detecting Recurrent Bladder Cancer

Recurrent bladder cancer can be detected through measuring a certain protein present in the urine. Where the US is concerned, bladder cancer is reported to be the fifth most malignant, which recorded 63,210 new cases in the year 2005 //year alone, with over 13,000 deaths. The country has a total of 500,000 patients with a bladder cancer history, and the chances of its recurrence is between 50% an...

More>>

Recurrent at Medicine Products
Recurrent at Medicine Technology

New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants

Prophylaxis with Synagis Decreases Incidence of Recurrent Wheeze byAlmost Half ABBOTT PARK, Ill. and GAITHERSBURG, Md., June 29, 2007/PRNewswire-FirstCall/ -- Abbott and MedImmune today announcedresults of a new study, published in the July issue of Journal ofPediatrics, showing that treatment with Synagis(R) (palivizumab)may reduce recurrent wheezing in premature infants by almosthalf.<...

Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer

WAILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announcedpreliminary results from two open-label, multi-center Phase 2clinical trials supporting the potential use of Xcytrin(R)(motexafin gadolinium) Injection, the company's lead productcandidate, in combination with Alimta(R) (pemetrexed) and incombination with Taxotere(R) (docetaxel...

Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma

CHICAGO and REGENSBURG - June 21, 2007 - “In anaplasticastrocytoma, AP 12009 as a monotherapy is actually clearly superiorto temozolomide,” Prof. Albert Wong, M.D., StanfordUniversity, California, U.S.A. commented on the international PhaseIIb study with the TGF-beta 2-inhibitor AP 12009, under developmentby Antisense Pharma. Prof. Wong discussed the results of the studyin th...

Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)

Phase II GBM study presented at ASCO with cediranib - a selectiveVEGF signaling inhibitor - shows over a quarter of patients aliveand progression- free at six months(1) CHICAGO, June 04, 2007 /PRNewswire/ -- Data for theinvestigational agent cediranib (AZD2171) were presented today atthe annual meeting of the American Society of Clinical Oncology(ASCO) from a study in patients with recurr...

Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer

- Data Support Rationale for Comprehensive Ongoing Phase 2 Programas Combination Agent with Standard Chemotherapies and Pivotal LungCancer Trial Scheduled to Begin Early Next Year - CHICAGO and SUNNYVALE, Calif. June 01, 2007/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announcedpromising preliminary results from an open-label Phase 2 clinicaltrial of Xcytrin(R) (motexafin gadoliniu...

More>>

Other Tags
(Date:1/7/2009)...s would work for ER patients with hypoxia remains ...ews) -- Going to the world,s most elevated natural...ve found that the established medical rules about ... might be wrong. , "Some people can tolerate extre...cted," said Dr. Michael P.W. Grocott, from Univers...
(Date:1/7/2009)..., Ohio, Jan. 7 SB 203, known as Emily,s Law, has ..., making the law official in the state of Ohio. Na...rict requirements and regulations for pharmacy tec...by Senator Tim Grendell, was drafted with assistan.... , , Emily,s Story , Emily Jerry died at the a...
(Date:1/7/2009)...ite to Provide Support and Convenience , , CARLS...nced the launch of a new on-line service for physi...kin care information and products. The new Web sit... between patients and their physicians while offer...chase. , , (Photo: http://www.newscom.com/cgi-...
(Date:1/7/2009)..., Ill., Jan. 7 BrainLAB, Inc., a leader in,softwa...cal treatments,announces a new, customer-focused s...nsideration of continued growth and an expanding p... and support structures, customers will benefit,fr...ion. Streamlined,responsibilities, communication, ...
Breaking Medicine News(10 mins):Health News:Study of Everest Climbers Questions Oxygen Use 2Health News:Study of Everest Climbers Questions Oxygen Use 3Health News:Emily's Law for Regulating Pharmacy Technicians Signed by Ohio Governor 2Health News:Emily's Law for Regulating Pharmacy Technicians Signed by Ohio Governor 3Health News:SkinMedica Launches On-Line Service for Physician Partners 2Health News:BrainLAB, Inc. Announces New, Streamlined Surgery Business Division 2
(Date:1/6/2009)...y at the University of Florida, has donated $250,0...or the establishment of an endowment to award crea...ty to find alternative solutions to problems that ...terest from the $250,000 will be presented to the ... for Innovation and Creativity in Entomology. , ...
(Date:1/6/2009)...ers have identified thousands of cell protein inte...ll that occur within cells of various organisms a... Such information will be critical to understandin...lfunctions in these processes contribute to cancer...nt teams of researchers has been somewhat inconsis...
(Date:1/6/2009)...scientists is linking nutrient pollution in the wo... harmful algal blooms reported in recent years. Wh...seafood with toxins, cause human respiratory and s...coastal waters. , In the December edition of th...mpilation of 21 articles outlining the role of nut...
(Date:1/6/2009)...rodegenerative diseases such as Alzheimer,s, strok...o name a few, has taken a step forward thanks to t... Do Carmo, supervised by Professor ric Rassart of ... Sciences Department, in collaboration with resear...versity of Valladolid in Spain. , Do Carmo and ...
Breaking Biology News(10 mins):Florida professor creates endowment for insect scientists 2Studies offer guide as protein interaction mapping comes of age 2Studies offer guide as protein interaction mapping comes of age 3Studies offer guide as protein interaction mapping comes of age 4A protein that protects against Alzheimer's? 2MAP Pharmaceuticals Announces Pricing of Its Initial Public Offering 1089 1MAP Pharmaceuticals Announces Pricing of Its Initial Public Offering 1089 2AspenBio Pharma to Present at the Oppenheimer Best Ideas 1x1 Conference 1087 1AspenBio Pharma to Present at the Oppenheimer Best Ideas 1x1 Conference 1087 2AspenBio Pharma to Present at the Oppenheimer Best Ideas 1x1 Conference 1087 3Surface Logix Presents Positive Phase 1 Repeat Dose Trial Data on SLx 4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism 454 1Surface Logix Presents Positive Phase 1 Repeat Dose Trial Data on SLx 4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism 454 2Surface Logix Presents Positive Phase 1 Repeat Dose Trial Data on SLx 4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism 454 369 New York Jets Continue Their Winning Ways 2991 169 New York Jets Continue Their Winning Ways 2991 269 New York Jets Continue Their Winning Ways 2991 369 New York Jets Continue Their Winning Ways 2991 469 New York Jets Continue Their Winning Ways 2991 5
Other Contentslymphomalymphomalymphomalymphomalymphomalymphedemamaculamaculamaculalymphocytelymphocytelymphocytelymphocytelymphocyteobstructionobstructionobstructionobstructionobstructionvenereumlymphogranuloma